MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41523-026-00952-x

Медицинская библиотека · NPJ breast cancer · 2026

WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.

Fiscalini Allison, Blum Kelly, Fergus Kirkpatrick, Hiatt Robert A, Naeim Arash, Kaster Andrea, Scheuner Maren T, van 't Veer Laura J, LaCroix Andrea Z, Borowsky Alexander D, Olopade Olufunmilayo I, Park Hannah L, Esserman James, Lancaster Rachael, Heditsian Diane, Brain Susie, Lee Vivian, Goodman Deborah L, Ross Katherine S, Wenger Neil, Parker Barbara A, Madlensky Lisa, Tice Jeffrey A, Shieh Yiwey, Ziv Elad, Arasu Vignesh A, Anton-Culver Hoda, Kaplan Celia P, Rhoads Kim F, Badal Kimberly, Hogarth Michael, Petruse Antonia, Soto Irene A, Leggat-Barr Katherine, Goodman Steffanie, Atamer Jennifer, Ryu Rita, Adduci Kelly, Matthews Jeffrey B, Eklund Martin, Athena/WISDOM Network Collaborators and Advocate Partners, Sabacan Leah P, Esserman Laura

СтатьяПеревод в очереди

Аннотация

The Women Informed to Screen Depending on Measures of risk (WISDOM) Study (clinicaltrials.gov NCT02620852, 2016-08-31) is pragmatic randomized controlled trial evaluating risk assessment to inform the age to start, frequency and modality of breast cancer screening and risk reduction. The WISDOM Study uses a preference-tolerant design, enabling women who decline randomization to self-select their screening arm. The risk-based arm included comprehensive breast cancer risk assessment using the Breast Cancer Surveillance Consortium (BCSC) model and genetics. From August 2016 to February 2023, WISDOM enrolled a large, diverse, nationwide cohort of 46,403 participants - 77% non-Hispanic (NH) White, 9% Hispanic, 6% (NH) Black, and 5% (NH) Asian; demographic diversity increased over time. Mean age at baseline was 54 years. 28,372 (61%) were randomized, while 89% of those who self-selected their screening arm chose risk-based screening. The preference-tolerant design captured real-world screening preferences while maintaining scientific rigor and demonstrated strong preference for risk-based screening.

Для цитирования: Fiscalini Allison, Blum Kelly, Fergus Kirkpatrick, Hiatt Robert A, Naeim Arash, Kaster Andrea, Scheuner Maren T, van 't Veer Laura J, LaCroix Andrea Z, Borowsky Alexander D, Olopade Olufunmilayo I, Park Hannah L, Esserman James, Lancaster Rachael, Heditsian Diane, Brain Susie, Lee Vivian, Goodman Deborah L, Ross Katherine S, Wenger Neil, Parker Barbara A, Madlensky Lisa, Tice Jeffrey A, Shieh Yiwey, Ziv Elad, Arasu Vignesh A, Anton-Culver Hoda, Kaplan Celia P, Rhoads Kim F, Badal Kimberly, Hogarth Michael, Petruse Antonia, Soto Irene A, Leggat-Barr Katherine, Goodman Steffanie, Atamer Jennifer, Ryu Rita, Adduci Kelly, Matthews Jeffrey B, Eklund Martin, Athena/WISDOM Network Collaborators and Advocate Partners, Sabacan Leah P, Esserman Laura. WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.. NPJ breast cancer. 2026. DOI: 10.1038/s41523-026-00952-x.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.